HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Belite Bio (NASDAQ:BLTE) and maintained a $59 price target for the company's stock.
November 15, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Belite Bio's stock rating has been reaffirmed as Buy by HC Wainwright & Co. with a price target of $59, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can lead to increased investor confidence and a potential short-term increase in the stock price. The specific mention of the company and the price target suggests a strong positive sentiment towards Belite Bio's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100